Abstract
Objectives Although insufficient delivery of oxygen might be a factor in physical and perceived fatigue, the relationship between exposure to hyperbaric oxygen (HBO) and recovery from perceived fatigue remains unexplained. The purpose of this study was to investigate the effects of exposure to HBO after long-duration, medium-intensity training on recovery from perceived fatigue in a single-blind study.
Methods Fatigue was induced in nine male university students (mean age: 21.3 years) using an ergometer exercise bike at a moderate intensity of 75% of their maximum heart rate for 60 min. Post-workout, subjects randomly received an intervention comprising exposure to HBO or an air placebo in a single-blind experimental trial. Blood tests were conducted, and perceived fatigue was evaluated by using visual analog scales (VAS) at five time points. One week later, a crossover trial was conducted.
Results For the HBO group, pre- to post-intervention mean VAS scores for whole-body fatigue significantly improved from 48.4 to 28.7 (p<0.001). However, in the placebo group, the improvement was not statistically significant. Hematological evaluations, including C-reactive protein level, white blood cell count, creatine kinase level, lactic acid level, T-cell count, CD4/CD8 ratio, and natural killer cell count, did not show any significant between-group differences except only BUN and free fatty acids levels 1.5 h after intervention and Mg levels immediately after intervention. There were also no significant differences in the results of other hematological assessments.
Conclusions The results of this study showed that perceived fatigue evaluated by VAS scores significantly improved in the HBO group in a blinded trial. However, this was not objectively supported by blood test results. HBO may have effects on recovery from perceived fatigue following long-duration, moderate-intensity exercise. However, the results of this study could not determine the efficacy of HBO on exercise-induced fatigue.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The trial registry is the ISRCTN registry, and the registration number is ISRCTN81080077. The reason why the study was not registered in advance was that this research was conducted in 2012, before the registration system was introduced.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the institutional review board of Tokyo Medical and Dental University
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.